- cafead   Aug 14, 2019 at 11:12: AM
via Myriad Genetics (NASDAQ: MYGN) stock soared earlier this month after the announcement that UnitedHealth Group will begin covering its GeneSight Psychotropic test beginning in October 2019. But investors hoping for more momentum with Myriad's latest quarterly results were sorely disappointed.
article source
article source